Ten years of research, and an 83 percent survival rate, shows that Gleevec, a cancer drug first developed by an Israeli, can fightt chronic myeloid leukemia.

Israeli scientists tried to find an explanation to the recurrence of cancer after chemotherapy and found that the source of returning leukemia is a set of unique cells that do not proliferate as quickly as regular cancer cells and are able to survive chemotherapy. The findings may have important implications for the future of cancer treatment.

Researchers from the Hebrew University of Jerusalem developed a new method to treat cancer using a protein extracted from the HIV virus. This protein can prevent the restoration of cancerous cells damaged by radiation therapy.

Eighteen shopping malls around Israel will later this month ask visitors to give a saliva sample to find a compatible bone marrow donor for a 12-and-a-half-year-old boy, Or Yosipov, who suffers from leukemia.